 |
|
|
| |
Analysis of Resistance in Virologic Failures during IFN/RBV Therapy Post 28-Day Treatment with MK7009:
Results through Week 24 of the Phase 2A
Dosing Finding Study in Genotype 1 Patients
|
| |
| |
Reported by Jules Levin
International HIV and Hepatitis Drug Resistance Workshop, June 8-12, 2010,
Dubrovnik, Croatia
Richard J.O. Barnard1, Adetoun Adeniji-Adele1, Richard Wiedmann2, Peggy M. Hwang3, Andrew W. Lee2, Amy Himmelberger1,
Michael D. Miller1, Daria Hazuda1
1Antiviral Research, 2ID/Vaccines Clinical Research, 3Biostatistics,
Merck Research Laboratories, West Point, PA, USA
This information remains the property of Merck and cannot be used or reprinted without their permission.
|
| |
|
|
|
|
|
